Conference News

GICS 2023 Monitoring ctDNA After Colorectal Cancer Surgery Cell-free DNA concentration is significantly increased in the first 2 weeks after surgery but these higher levels do not seem to interfere with monitoring of circulating tumor DNA for prognostic purposes.
News, February 02, 2023
SCCM 2023 Genetic Testing in the PICU Prompts Meaningful Changes in Care A multicenter study showed the potential value of rapid whole genome sequencing to impact care of critically ill children.
News, January 31, 2023
SCCM 2023 Citing Workplace Violence, a Quarter of HCWs Are Ready to Quit Data from 69 countries show the toll that violence in the workplace takes on our healthcare system.
News, January 30, 2023
GICS 2023 Regorafenib: New Option for Advanced Gastroesophageal Cancer? In patients with advanced refractory gastroesophageal cancer who had tried two other options, regorafenib improved overall survival when compared with placebo, offering a potential new treatment option.
News, January 24, 2023
GICS 2023 SUNLIGHT: New Standard of Care in Refractory Metastatic CRC The SUNLIGHT trial results show that adding bevacizumab to trifluridine/tipiracil (Lonsurf) improves median overall and progression free survival without increasing the risk for serious adverse events.
News, January 23, 2023
GICS 2023 Adding SBRT to Sorafenib Boosts Survival in Liver Cancer Adding stereotactic body radiation therapy (SBRT) to treatment with sorafenib improved overall survival and progression-free survival as well as quality of life.
News, January 23, 2023
GICS 2023 New 'Reference Regimen' in Metastatic Pancreatic Cancer? Liposomal irinotecan plus chemo in the new NALIRIFOX regimen significantly improved overall survival compared with standard therapy in metastatic pancreatic ductal adenocarcinoma.
News, January 23, 2023
GICS 2023 Longest Overall Survival Ever Seen in Advanced Gastric Cancer The combination of zolbetuximab plus chemotherapy produced one of the longest overall survival outcomes ever seen for patients with advanced caludin18.2+ gastric or gastroesophageal junction cancer.
News, January 20, 2023
SABCS 2022 HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact? One of the problems with the new subgroup of HER2 low tumors is that using current assays to measure low levels "is like weighing mice on a scale built for elephants," says one expert.
News, January 05, 2023
IDF 2022 New Efforts to Aid Those With Diabetes in Humanitarian Crises A recently launched multisector partnership is gearing up to provide lifesaving assistance for people with diabetes in natural and man-made disaster situations.
News, December 28, 2022
SABCS 2022 Six Obstacles in Breast Cancer Detection and Treatment At a recent conference, oncologists outlined key challenges that need to be addressed to improve breast cancer diagnosis and treatment.
News, December 27, 2022
SABCS 2022 Who Benefits From 5 Years of Extended Endocrine Therapy? MammaPrint genomic testing suggests that only patients with low-risk, not ultra-low-risk or high-risk, breast cancer benefit from 5 years of extended endocrine therapy.
News, December 22, 2022
ACEP 2022 What Lies Ahead for Prehospital Critical Care Resuscitation An intensivist shared a (not so distant) futurist view of resuscitative endovascular balloon occlusion of the aorta (REBOA) and extracorporeal membrane oxygenation (ECMO) life support.
News, December 21, 2022
IDF 2022 Debate: Lifestyle or Surgery for Type 2 Diabetes Remission? What is the evidence supporting intensive lifestyle modification vs bariatric surgery for type 2 diabetes remission? Experts discussed this at the recent International Diabetes Federation meeting.
News, December 21, 2022
AES 2022 Using Seizure-Risk Forecasts for Best Epilepsy Monitoring Time Scheduling video EEG monitoring on the basis of personalized seizure risk forecasts could improve diagnostic accuracy, emerging research suggests.
News, December 19, 2022
RSNA 2022 Corticosteroid Injections May Worsen Knee OA Progression Corticosteroid knee injections appear to make knee osteoarthritis worse, and hyaluronic acid injections may be safer, two research teams report.
News, December 19, 2022
IDF 2022 Dubious Diagnosis: Is There a Better Way to Define 'Prediabetes'? Epidemiologist suggests that until better definitions are established, use of both fasting glucose and A1c cutoffs define a group at particularly high risk of going on to develop type 2 diabetes.
News, December 19, 2022
ACR 2022 Rheumatology Workforce Shortage Demands Multipronged Approach Members of the American College of Rheumatology's Workforce Solutions Committee outlined a multitude of ways in which the society aims to marshal local, regional, and national resources and programs.
News, December 16, 2022
AES 2022 High Retention, Seizure-Freedom Rates for Perampanel in Epilepsy Early results from the PERPRISE study showed high retention and seizure-freedom rates among adults with focal or idiopathic generalized epilepsy who received perampanel as add-on therapy.
News, December 15, 2022
IDF 2022 Spotlight on 'Alarming' Diabetes Rates in Indigenous Populations A new report added to the IDF 2021 Diabetes Atlas details the 'incredibly' high prevalence of type 2 diabetes among indigenous people worldwide.
News, December 15, 2022

No Results